6-OHDA is a catecholaminergic neurotoxin that has been used to induce dopaminergic lesions and parkinsonian symptoms as a model of Parkinson''s disease in rodents. It induces locomotor impairment in mice and loss of tyrosine hydroxylase-reactive neurons in mouse brain when administered into the substantia nigra, medial forebrain bundle (MFB), or striatum at doses of 9, 6, and 18 μg, respectively. Intracisternal administration of 6-OHDA (200 μg) decreases dopamine and norepinephrine levels in rat brain. It induces apoptosis in primary rat cortical cells and PC12 rat adrenal cells when used at a concentration of 50 μM. 6-OHDA (75 μM) activates caspase-3, -8, and -9 in a time-dependent manner and increases the level of intracellular reactive oxygen species (ROS) in PC12 cells and induces apoptosis in rat substantia nigra when stereotaxically injected into the right MFB.
beige to brown crystalline powder
6-Hydroxydopamine is a selective catecholaminergic neurotoxin. Studies show that 6-Hydroxydopamine can be used to create an animal model of Parkinson''s disease as it causes almost complete destruction of nigral dopaminergic neurons and their striatal terminals when injected into the substantia nigra of rats. 6-Hydroxydopamine induces apoptosis in PC12 cells.
Solutions should be freshly prepared and protected from exposure to light.
Neurotoxin that destroys catecholaminergic terminals.
